Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
The present invention relates to characterizing changes in mammalian gastrointestinal microbiota associated with antibiotic treatment and various disease conditions (such as obesity, metabolic syndrome, insulin-deficiency or insulin-resistance related disorders, glucose intolerance, diabetes, non-alcoholic fatty liver, abnormal lipid metabolism, short stature, osteoporosis, and other disorders of bone formation and mineralization, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial gastrointestinal microbiota.
1. A method of treating a disease in a mammal in need thereof, wherein the disease is selected from the group consisting of osteoporosis and other disorders of bone formation and mineralization, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition comprising one or more conditionally lethal bacterial strains, wherein the composition (i) stimulates the growth or activity of one or more bacterial taxa which are under-represented in microbiota of the mammal as compared to a healthy control or (ii) inhibits the growth or activity of one or more bacterial taxa which are over-represented in microbiota of the mammal as compared to a healthy control.
2. The method of claim 1 , wherein the bacterial strain contained in the probiotic composition is a Helicobacter pylori strain.
3. The method of claim 1 , wherein the probiotic composition further comprises a buffering agent selected from the group consisting of sodium bicarbonate, milk, yogurt, and infant formula.
4. The method of claim 1 , wherein the microbiota are gastrointestinal microbiota.
5. The method of claim 1 , wherein the probiotic composition is administered orally.
6. The method of claim 1 , wherein the healthy control is a healthy subject of the same age and gender as the mammal being treated or an average of several healthy subjects of the same gender and average age as the mammal being treated.
7. The method of claim 1 , wherein the mammal is human.
8. The method of claim 1 , further comprising administering a prebiotic, wherein the prebiotic (i) stimulates growth or activity of one or more bacterial taxa which are under-represented in microbiota of the mammal as compared to the healthy control or (ii) inhibits growth or activity of one or more bacterial taxa which are over-represented in microbiota of the mammal as compared to the healthy control.
9. The method of claim 1 , wherein the probiotic composition further comprises a prebiotic which stimulates growth or activity of the one or more bacterial strains in said composition.
10. The method of claim 1 , said method further comprising identifying under-represented and/or over-represented bacterial taxa in the microbiota from the mammal as compared to a healthy control.
11. The method of claim 10 , wherein identifying under-represented or over-represented bacterial taxa involves screening bacterial 16S rRNA genes using PCR.
12. The method of claim 10 , wherein identifying under-represented or over-represented bacterial taxa involves high-throughput sequencing or PCR methods.
13. The method of claim 10 , wherein identifying under-represented or over-represented bacterial taxa involves transciptomic or proteomic studies.
14. The method of claim 10 , wherein the bacterial strain contained in the probiotic composition is a live bacterial strain.
15. The method of claim 10 , wherein the bacterial strain contained in the probiotic composition is a conditionally lethal bacterial strain.
16. The method of claim 10 , wherein the bacterial strain contained in the probiotic composition is a Helicobacter pylori strain.
17. The method of claim 10 , wherein the probiotic composition further comprises a buffering agent selected from the group consisting of sodium bicarbonate, milk, yogurt, and infant formula.
18. The method of claim 10 , wherein the microbiota are gastrointestinal microbiota.
19. The method of claim 10 , wherein the probiotic composition is administered orally.
20. The method of claim 10 , wherein the healthy control is a healthy subject of the same age and gender as the mammal being treated or an average of several healthy subjects of the same gender and average age as the mammal being treated.
21. The method of claim 10 , wherein the mammal is human.
22. The method of claim 10 , further comprising administering a prebiotic, wherein the prebiotic (i) stimulates growth or activity of one or more bacterial taxa which are under-represented in microbiota of the mammal as compared to the healthy control or (ii) inhibits growth or activity of one or more bacterial taxa which are over-represented in microbiota of the mammal as compared to the healthy control.
23. The method of claim 10 , wherein the probiotic composition further comprises a prebiotic which stimulates growth or activity of the one or more bacterial strains in said composition.
24. A method of treating a disease in a mammal in need thereof, wherein the disease is selected from the group consisting of osteoporosis and other disorders of bone formation and mineralization, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition comprising a Helicobacter pylori strain, wherein the composition (i) stimulates the growth or activity of one or more bacterial taxa which are under-represented in microbiota of the mammal as compared to a healthy control or (ii) inhibits the growth or activity of one or more bacterial taxa which are over-represented in microbiota of the mammal as compared to a healthy control.
25. The method of claim 24 , wherein the Helicobacter pylori strain contained in the probiotic composition is a live strain.
26. The method of claim 24 , wherein the Helicobacter pylori strain contained in the probiotic composition is a conditionally lethal strain.
27. The method of claim 24 , wherein the probiotic composition further comprises a buffering agent selected from the group consisting of sodium bicarbonate, milk, yogurt, and infant formula.
28. The method of claim 24 , wherein the microbiota are gastrointestinal microbiota.
29. The method of claim 24 , wherein the probiotic composition is administered orally.
30. The method of claim 24 , wherein the healthy control is a healthy subject of the same age and gender as the mammal being treated or an average of several healthy subjects of the same gender and average age as the mammal being treated.
31. The method of claim 24 , wherein the mammal is human.
32. The method of claim 24 , further comprising administering a prebiotic, wherein the prebiotic (i) stimulates growth or activity of one or more bacterial taxa which are under-represented in microbiota of the mammal as compared to the healthy control or (ii) inhibits growth or activity of one or more bacterial taxa which are over-represented in microbiota of the mammal as compared to the healthy control.
33. The method of claim 24 , wherein the probiotic composition further comprises a prebiotic which stimulates growth or activity of the Helicobacter pylori strain in said composition.
34. A method of treating a disease in a mammal in need thereof, wherein the disease is selected from the group consisting of osteoporosis and other disorders of bone formation and mineralization, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition comprising one or more bacterial strains, wherein the probiotic composition further comprises sodium bicarbonate, and (i) stimulates the growth or activity of one or more bacterial taxa which are under-represented in microbiota of the mammal as compared to a healthy control or (ii) inhibits the growth or activity of one or more bacterial taxa which are over-represented in microbiota of the mammal as compared to a healthy control.
35. The method of claim 34 , wherein the bacterial strain contained in the probiotic composition is a live bacterial strain.
36. The method of claim 34 , wherein the healthy control is a healthy subject of the same age and gender as the mammal being treated or an average of several healthy subjects of the same gender and average age as the mammal being treated.
37. The method of claim 34 , wherein the mammal is human.
38. The method of claim 37 , wherein the healthy control is a healthy human of the same age, gender and ethnicity as the human being treated or an average of several healthy humans of the same gender, ethnicity and average age as the human being treated.
39. The method of claim 34 , wherein the microbiota are gastrointestinal microbiota.
40. The method of claim 34 , wherein the probiotic composition is administered orally.
41. The method of claim 34 , further comprising administering a prebiotic, wherein the prebiotic (i) stimulates growth or activity of one or more bacterial taxa which are under-represented in microbiota of the mammal as compared to the healthy control or (ii) inhibits growth or activity of one or more bacterial taxa which are over-represented in microbiota of the mammal as compared to the healthy control.
42. The method of claim 34 , wherein the probiotic composition further comprises a prebiotic which stimulates growth or activity of the one or more bacterial strains in said composition.
43. The method of claim 34 , wherein the bacterial strain contained in the probiotic composition is a conditionally lethal bacterial strain.
44. The method of claim 34 , wherein the bacterial strain contained in the probiotic composition is a Helicobacter pylori strain.
45. A method of treating a disease in a mammal in need thereof, wherein the disease is selected from the group consisting of osteoporosis and other disorders of bone formation and mineralization, said method comprising administering to the mammal a therapeutically effective amount of a probiotic composition comprising one or more bacterial strains, wherein the probiotic composition stimulates the growth or activity of one or more species of Lachnospiraceae.
46. The method of claim 45 , wherein the bacterial strain contained in the probiotic composition is a live bacterial strain.
47. The method of claim 45 , wherein the bacterial strain contained in the probiotic composition is a conditionally lethal bacterial strain.
48. The method of claim 45 , wherein the bacterial strain contained in the probiotic composition is a Helicobacter pylori strain.
49. The method of claim 45 , wherein the probiotic composition further comprises a buffering agent selected from the group consisting of sodium bicarbonate, milk, yogurt, and infant formula.
50. The method of claim 45 , wherein the microbiota are gastrointestinal microbiota.
51. The method of claim 45 , wherein the probiotic composition is administered orally.
52. The method of claim 45 , wherein the mammal is human.
53. The method of claim 45 , further comprising administering a prebiotic, wherein the prebiotic stimulates growth or activity of one or more species of Lachnospiraceae.
54. The method of claim 45 , wherein the probiotic composition further comprises a prebiotic which stimulates growth or activity of the one or more bacterial strains in said composition.